Company Profile
ARS Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- SPRY
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.55 USD (+3.54%)
Close
Last updated: August 6, 2026
884M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SPRY closed up 3.54% at $5.55. No new same-company headline was identified in the current news window.
Company overview
Needle-Free Epinephrine Company
ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union.
Neffy Commercialization
The company is building U.S. sales, payer access, prescription-refill programs, and pharmacy affordability support while expanding internationally through regional partners. Health Canada has approved neffy, with ALK responsible for Canadian commercialization.
Patient-Centered Delivery Strategy
The nasal formulation is intended to remove barriers associated with injectable epinephrine, including needle anxiety, complex administration, and hesitation during emergencies. ARS is building its commercial strategy around portability, ease of use, and broader willingness to carry treatment.
Intranasal Epinephrine Platform Expansion
Beyond emergency allergy treatment, ARS is evaluating intranasal epinephrine for acute flares of chronic spontaneous urticaria and has advanced the program into a Phase 2b study.
International Partnership Model
ARS uses regional partners to extend neffy beyond its direct U.S. commercial organization. These partners assume responsibility for local regulatory, distribution, and launch activities while broadening the geographic value of the product.
Future catalysts
ALK is expected to launch neffy in Canada later in 2026.
Interim data from the Phase 2b study of intranasal epinephrine in chronic spontaneous urticaria are expected in the fourth quarter of 2026.
If the Phase 2b results are supportive, a single pivotal Phase 3 efficacy study could begin in mid-2027.
Recent news
- 01
- 02
ARS Pharmaceuticals Announces CEO Succession
Source: ARS Pharmaceuticals
- 03
ARS Pharmaceuticals Provides Commercial and Financial Updates
Source: ARS Pharmaceuticals
- 04
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
Source: ARS Pharmaceuticals
- 05
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
Source: ARS Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ARS Pharmaceuticals (SPRY)?
ARS Pharmaceuticals (SPRY) most recently closed at 5.55 USD, a +3.54% move versus the previous session.
What is the market cap of ARS Pharmaceuticals (SPRY)?
ARS Pharmaceuticals currently has a market capitalization of 884M USD on BioPharmSignal.
What does ARS Pharmaceuticals do?
Needle-Free Epinephrine Company ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union. Neffy Commercialization The company is building U.S. sales, payer access, prescription-refill...
On which exchange is SPRY stock listed?
ARS Pharmaceuticals (SPRY) is associated with NASDAQ, United States, Biopharma.
What is Needle-Free?
Needle-Free Epinephrine Company ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis.
Which conditions is ARS Pharmaceuticals targeting with Needle-Free?
Needle-Free Epinephrine Company ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union. Neffy Commercialization The company is building U.S. sales, payer access, prescription-refill...
How does ARS Pharmaceuticals describe recent progress with Needle-Free?
ALK is expected to launch neffy in Canada later in 2026. Interim data from the Phase 2b study of intranasal epinephrine in chronic spontaneous urticaria are expected in the fourth quarter of 2026. If the Phase 2b results are supportive, a single pivotal Phase 3 efficacy study could begin in mid-2027.
What is Epinephrine?
Needle-Free Epinephrine Company ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis.